Multiple sclerosis diagnosis in early stag...Belgian and German researchers have presented a new imaging tool that can track immune cells invading the brain in the initial stages of multiple sclerosis (MS). more ➔
BIO Europe with new record numbers Despite declining numbers of IPOs, financing rounds and licensing deals, the European biotech sector presented itself optimistic and self-confident during BIO-Europe in Cologne. The three-days partnering … more ➔
AZ withdraws lung cancer drug from EU lead...After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German … more ➔
Bioregions deliver action plan blueprintWhile DG Research has delayed its update on the European Bioeconomy Strategy and Action Plan until next June, the Central and Eastern Bioregions presented a blueprint that proposes key actions aimed … more ➔
Germany lagging behind in stem cell resear...A new analysis comparing the amount of funding invested into stem cell research clearly demonstrates declining investment in Germany. In contrast, the US, the UK, Sweden and Japan have increased their … more ➔
Belgian Fund+ raises €125m for biotechsInvestors are once again flocking to back biotechs in Europe. Belgian Life Sciences fund Fund+ has raised €125m – a quarter more than initially anticipated. more ➔
ETH builds cyborg bacteriaPart microbe, part machine: cyborg bacteria developed at ETH Zurich could revolutionise the biotechnological production of molecules. The bacteria have been engineered to respond to light signals. more ➔
Nordic Nanovector in blood cancer pactNordic Nanovector is expanding its foothold in cancer-fighting ADCs. The Oslo-based biotech has inked a leukaemia pact with Wilex subsidiary Heidelberg Pharma. more ➔
EMA unveils trial dataTrial transparency has been a hotly debated topic over the last months, but now, the EMA is turning words into action. The agency will allow public access to clinical trial reports, starting now. more ➔
Dilaforette: Going public with a new nameNew name, new outlook: blood disorder specialist Dilaforette will be known as Modus Therapeutics Holding from here on out. The Swedish company also announced an intention to float in the near future. more ➔
